Sanofi decided to discontinue the development of its experimental Clostridium difficile vaccine.
Clostridium difficile is a bacterium that causes diarrhea and more serious intestinal conditions.
The company said its decision is based on an analysis by an independent data monitoring committee, which concluded that the probability of the vaccine meeting its primary objective in a phase 3 trial was low.
Sanofi was testing the vaccine in people at risk of the infection.
Sanofi Pasteur, the vaccines business of Sanofi responsible for the program, is informing all investigators, regulatory authorities and trial ethics committees.
Additionally, investigators are notifying study volunteers of the decision.
